Butterfly Network CFO and CBO sell shares at $1.5 each on September 4, 2025.
PorAinvest
lunes, 8 de septiembre de 2025, 5:01 pm ET1 min de lectura
BFLY--
The share sales coincide with the publication of a significant study in The Journal of the American Medical Association (JAMA Network Open) that validates the use of Butterfly's ultrasound technology in improving patient care and hospital efficiency. The study, led by researchers at Rutgers Robert Wood Johnson Medical School (RWJMS) and supported by Butterfly Network, found that integrating a hospitalist POCUS workflow, heavily focused on lung ultrasound (LUS) for pulmonary congestion and assisted by an FDA-cleared Auto B-line Counter, reduced length of stay and hospitalization costs [1].
The study, titled "POCUS for Cardiopulmonary Assessment and Resource Evaluation (POCUS-CARE) trial," involved 208 patients and demonstrated a 30% reduction in expected hospital length of stay, saving 246 bed-days and $751,537 in direct costs. The incremental cost-effectiveness ratio was $3,055 per hospital bed day saved, underscoring the economic value of integrating POCUS into inpatient care [1].
The study reflects Butterfly's commitment to generating high-quality clinical evidence in support of scalable, sustainable POCUS integration across the healthcare continuum. By pairing hospitalist-led lung ultrasound with AI Auto B-line Counter and cloud workflows, teams could standardize and speed congestion assessment, supporting earlier, better-informed decisions and hospital efficiency [1].
References:
[1] https://www.marketscreener.com/news/butterfly-network-rutgers-robert-wood-johnson-medical-school-study-published-in-jama-confirms-butt-ce7d59d9dd80fe23
Butterfly Network, Inc. [BFLY] has announced that Interim Chief Financial Officer Megan Carlson sold 13,803 shares at $1.5 per share on September 4, 2025. Additionally, Chief Business Officer Steve Cashman sold 142,590 shares at the same price on the same date.
Butterfly Network, Inc. [BFLY], a digital health company specializing in portable ultrasound technology, has seen its executives sell shares recently. On September 4, 2025, Interim Chief Financial Officer Megan Carlson sold 13,803 shares at $1.5 per share, while Chief Business Officer Steve Cashman sold 142,590 shares at the same price [1].The share sales coincide with the publication of a significant study in The Journal of the American Medical Association (JAMA Network Open) that validates the use of Butterfly's ultrasound technology in improving patient care and hospital efficiency. The study, led by researchers at Rutgers Robert Wood Johnson Medical School (RWJMS) and supported by Butterfly Network, found that integrating a hospitalist POCUS workflow, heavily focused on lung ultrasound (LUS) for pulmonary congestion and assisted by an FDA-cleared Auto B-line Counter, reduced length of stay and hospitalization costs [1].
The study, titled "POCUS for Cardiopulmonary Assessment and Resource Evaluation (POCUS-CARE) trial," involved 208 patients and demonstrated a 30% reduction in expected hospital length of stay, saving 246 bed-days and $751,537 in direct costs. The incremental cost-effectiveness ratio was $3,055 per hospital bed day saved, underscoring the economic value of integrating POCUS into inpatient care [1].
The study reflects Butterfly's commitment to generating high-quality clinical evidence in support of scalable, sustainable POCUS integration across the healthcare continuum. By pairing hospitalist-led lung ultrasound with AI Auto B-line Counter and cloud workflows, teams could standardize and speed congestion assessment, supporting earlier, better-informed decisions and hospital efficiency [1].
References:
[1] https://www.marketscreener.com/news/butterfly-network-rutgers-robert-wood-johnson-medical-school-study-published-in-jama-confirms-butt-ce7d59d9dd80fe23

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios